Pfizer Inc. has completed enrolling children aged 12 to 15 in a COVID-19 vaccine study, the drug maker confirmed Friday. 

Pfizer said the Phase 3 clinical trial began in late July 2020 and completed enrollment of 46,331 participants in January, including over 2,200 participants aged 12-15. The company also plans to study the vaccine in pregnant women, among other populations. 

Vaccines from Pfizer and Moderna Inc. are not currently available for use in children due to a lack of studies. The Food and Drug Administration last month authorized emergency use of the vaccine for individuals age 16 and older. 

Related News Articles

Blog
The American Hospital Association and its Society for Healthcare Strategy and Market Development (SHSMD) July 15 hosted “Addressing COVID-19 Vaccine Hesitancy…
Headline
Read a recap and insights from health care leaders during AHA’s July 15 webinar, “Addressing COVID-19 Vaccine Hesitancy in Your Community,” featuring messaging…
Headline
Three-quarters of the 469 COVID-19 cases associated with summer events and large public gatherings this month in Barnstable County, Mass., were in people fully…
Headline
About 8.9 million children aged 12-17 have received the Pfizer COVID-19 vaccine, the Centers for Disease Control and Prevention reported today. Based on data…
Headline
President Biden today announced new actions to spur more vaccinations nationwide against COVID-19, due in part to the rise of the SARS-CoV-2 delta variant.…
Headline
The AHA today released new Spanish-language public service announcements and related content pieces to support vaccination efforts and complement previously…